[September 16, 2014] |
|
Panagene Succeeds in Developing 'ctDNA Mutation Test' Kit Launching a Total of 4 Breakthrough Commercial Products for Cancer Diagnostics
SEOUL, South Korea --(Business Wire)--
Panagene has been in focus on news of having developed a commercial
ctDNA test kits that can detect mutated oncogene through blood test
alone. This technology is based on PNA (Peptide Nucleic Acid) and it can
detect various mutated oncogenes in real-time.
Panagene (President Sung Kee Kim), a Korea company specializing in
molecular diagnostics, announced the successful development of the
'C-melting technology'. Unlike traditional diagnostic products for
invasive biopsy samples, this innovative ultra-sensitive test method
makes it easy to effectively detect mutation from ctDNA in blood - as
little as 0.01% of mutant ctDNA among excess of wild-type in blood can
be detected in less than 3 hours.
The company explained "'C-melting technology' enabled this inovative,
non-invasive, and easy method to accurately identify mutated oncogenes,
unlike the 'PNAClamp technology', which is mainly used for invasive
tissue biopsy".
A total of four products were launched with this technology applied.
These products are targeted to detect lung and colorectal cancer
biomarkers such as EGFR, KRAS, and NRAS: PANAMutyperTM R
EGFR T790M, PANAMutyperTM R EGFR L858R, PANAMutyperTM
R KRAS series, and PANAMutyperTM R NRAS series. These
products are research use only, and regulatory approval process is
currently underway.
The company stated "Our KRAS and NRAS ctDNA kits can accurately classify
19 and 20 genotypes of mutation, respectively, and EGFR ctDNA kit can
identify acquired drug-resistance mutation induced by targeted-therapy."
and "It's not just about pioneering the new market of cancer diagnostics
in blood tests. We anticipate this breakthrough to facilitate the
development of new anticancer drugs that are aimed to target each
mutation variant".
Panagene Inc. is a leading PNA (Peptide Nucleic Acid) oligomer
manufacturer, has developed various products based on PNA. In addition,
the company has successfully commercialized diagnostic products in the
domestic and competitive global markets. Panagene also specializes in
mass production of PNA with strong patent portfolios and supplies
products to more than 200 organizations in over 30 countries.
[ Back To TMCnet.com's Homepage ]
|